Skip to main content

Search

Reset all filters
152 Result(s)
Sort by

Rewards and recognition

Rewards and recognition

There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Learning and development

Learning and development

We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Alexander Guntur

Alexander Guntur

Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
Andreas Lenk

Andreas Lenk

Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Ethics and Compliance

Ethics and Compliance

Consistent with the Core of our Leitbild and Code of Conduct, we act with integrity and are committed to conducting business in a lawful and ethical manner.
CONTINUUM

CONTINUUM

CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
Anna Mezentseva

Anna Mezentseva

Anna Mezentseva talks about being a discovery management trainee in Finance and Controlling.
Irene Anindita

Irene Anindita

Irene Anindita is a Multichannel Manager for Cardiovascular and Metabolism Team in Amsterdam, the Netherlands, and really loves the vibe.
Christina Schmitt

Christina Schmitt

Christina Schmitt loves that she can be creative every day as a biopharma management trainee at Boehringer Ingelheim.
Daniel Kiesenhofer

Daniel Kiesenhofer

Daniel Kiesenhofer talks about his role as Project Manager Quality Control at Boehringer Ingelheim in Vienna, Austria.
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Galym Zhunisbekov

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Nadine Becker

Nadine Becker

Nadine Becker, speaks about her role in the Master Data Management and her 20 year career in Boehringer Ingelheim.
Liliana Montano

Liliana Montano

Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Alex Breiner

Alex Breiner

Alex Breiner, a Senior Communications Manager in Corporate Affairs, highlights his career and the many development programmes at Boehringer Ingelheim.